Work

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-147581

Authors: Sattva S. Neelapu, Mehdi Hamadani, Don Stevens, Sandra M. Hayes, Francesco Galimi, David B. Miklos

Institutions: The University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, Norton Healthcare, Norton Hospital, Stanford Medicine, Stanford University

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213505915

Cites:

Cited by: 10

Related to: 10